533 related articles for article (PubMed ID: 30075950)
1. The visual prostate symptom score is a simple tool to identify and follow up in general practice patients with lower urinary tract symptoms associated with benign prostatic hyperplasia (a study with 1359 patients).
Descazeaud A; Coloby P; Taille A; Karsenty G; Kouri G; Rossi D; Carrois F; Zerbib M
Presse Med; 2018; 47(7-8 Pt 1):e91-e98. PubMed ID: 30075950
[TBL] [Abstract][Full Text] [Related]
2. [Validation of visual prostate symptom score, VPSS, in the evaluation of lower urinary tract symptoms associated with benign prostatic hyperplasia (550 patients)].
Descazeaud A; Coloby P; Davin JL; De La Taille A; Karsenty G; Kouri G; Rossi D; Pouteau JC; Zerbib M
Prog Urol; 2017 Mar; 27(3):176-183. PubMed ID: 28285780
[TBL] [Abstract][Full Text] [Related]
3. [Interest of a systematic assessment of the treatment of the lower urinary tract symptoms in the management of benign prostatic hypertrophy in general practice (1380 patients) - Study EVALURO].
Descazeaud A; Coloby P; De La Taille A; Kouri G; Mallet R; Rossi D; Rozet F; Zerbib M; Carrois F
Prog Urol; 2019 Feb; 29(2):116-126. PubMed ID: 30665818
[TBL] [Abstract][Full Text] [Related]
4. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up.
Porpiglia F; Fiori C; Bertolo R; Garrou D; Cattaneo G; Amparore D
BJU Int; 2015 Aug; 116(2):278-87. PubMed ID: 25382816
[TBL] [Abstract][Full Text] [Related]
5. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
6. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
[TBL] [Abstract][Full Text] [Related]
7. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
[TBL] [Abstract][Full Text] [Related]
8. Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.
Fujimura T; Kume H; Nishimatsu H; Sugihara T; Nomiya A; Tsurumaki Y; Miyazaki H; Suzuki M; Fukuhara H; Enomoto Y; Homma Y
BJU Int; 2012 May; 109(10):1512-6. PubMed ID: 21883834
[TBL] [Abstract][Full Text] [Related]
9. Correlation of Subjective Symptoms in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction.
Kardasevic A; Milicevic S
Med Arch; 2017 Feb; 71(1):32-36. PubMed ID: 28428671
[TBL] [Abstract][Full Text] [Related]
10. Can benign prostatic hyperplasia be identified in the primary care setting using only simple tests? Results of the Diagnosis IMprovement in PrimAry Care Trial.
Carballido J; Fourcade R; Pagliarulo A; Brenes F; Boye A; Sessa A; Gilson M; Castro R
Int J Clin Pract; 2011 Sep; 65(9):989-96. PubMed ID: 21733048
[TBL] [Abstract][Full Text] [Related]
11. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up.
Porpiglia F; Fiori C; Amparore D; Kadner G; Manit A; Valerio M; Nicolaas L; Ho BSH; Alonso S; Schulman C; Barber N
BJU Int; 2019 Jun; 123(6):1061-1069. PubMed ID: 30382600
[TBL] [Abstract][Full Text] [Related]
12. Do baseline estrogen and testosterone affect lower urinary tract symptoms (LUTS) prior to or after pharmacologic treatment with tadalafil?
Egan KB; Miner MM; Suh M; McVary K; Ni X; Roehrborn CG; Wittert G; Wong DG; Rosen RC
Andrology; 2015 Nov; 3(6):1165-72. PubMed ID: 26452447
[TBL] [Abstract][Full Text] [Related]
13. Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.
Brock G; Broderick G; Roehrborn CG; Xu L; Wong D; Viktrup L
BJU Int; 2013 Nov; 112(7):990-7. PubMed ID: 23937669
[TBL] [Abstract][Full Text] [Related]
14. Accuracy of a "Single Question Nocturia Score" compared to the "International Prostate Symptoms Score" in the evaluation of lower urinary tract symptoms in benign prostatic hyperplasia: A study performed at Ndola Teaching Hospital, Ndola, Zambia.
Kajimotu T; Bowa K
PLoS One; 2018; 13(6):e0198096. PubMed ID: 29944653
[TBL] [Abstract][Full Text] [Related]
15. Construct validation of patient global impression of severity (PGI-S) and improvement (PGI-I) questionnaires in the treatment of men with lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Viktrup L; Hayes RP; Wang P; Shen W
BMC Urol; 2012 Nov; 12():30. PubMed ID: 23134716
[TBL] [Abstract][Full Text] [Related]
16. A multicenter real-life study of the efficacy of an alpha-blocker with or without anticholinergic agent (imidafenacin) treatment in patients with lower urinary tract symptoms/benign prostatic hyperplasia and storage symptoms.
Cho S; Kwon SS; Lee KW; Yoo TK; Shin DG; Kim SW; Bae JH; Choi H; Kim YH
Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28508455
[TBL] [Abstract][Full Text] [Related]
17. The association of endothelial nitric oxide synthase (eNOS) G894T gene polymorphism with responsiveness to a selective α1 -blocker in men with benign prostatic hyperplasia related lower urinary tract symptoms.
Lee YC; Juan YS; Liu CC; Bao BY; Wang CJ; Wu WJ; Huang CN; Huang SP
BJU Int; 2016 Aug; 118(2):313-9. PubMed ID: 26940040
[TBL] [Abstract][Full Text] [Related]
18. Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.
Fourcade RO; Lacoin F; Rouprêt M; Slama A; Le Fur C; Michel E; Sitbon A; Cotté FE
World J Urol; 2012 Jun; 30(3):419-26. PubMed ID: 21892656
[TBL] [Abstract][Full Text] [Related]
19. Correlation between international prostate symptom score and uroflowmetry in patients with benign prostatic hyperplasia.
Oranusi CK; Nwofor AE; Mbonu O
Niger J Clin Pract; 2017 Apr; 20(4):454-458. PubMed ID: 28406126
[TBL] [Abstract][Full Text] [Related]
20. [The results of the multicenter prospective comparative study of Androgel in men with endogenous testosterone deficiency and lower urinary tract symptoms, associated with benign prostate hyperplasia (POTOK)].
Kogan MI; Avadieva NE; Gevorkyan LS; Loginov YA; Metelkin AM; Mitin AA; Patrikeev AA
Urologiia; 2023 May; (2):32-40. PubMed ID: 37401702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
